Of Interest

The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but their immune targets differ.

Researchers at The University of Sydney have identified a significant increase in melanoma-related death risk for patients with thin primary tumors measuring between 0.8 and 1.0 millimeters compared to those with thinner lesions.

Conducted as part of the MELCAYA project, the study demonstrates that anti PD-1 antibody immunotherapy is safe for children and adolescents. Furthermore, whilst it is effective for patients who have previously had their tumour removed, its effectiveness is diminished in more advanced cases, where metastasis has already spread to other organs.

Mohs micrographic surgery with melanocytic immunostains (MMS-I) is emerging as an effective treatment option for invasive melanomas, particularly in anatomically constrained areas, due to a low risk of local recurrence and disease-specific mortality, according to study results published in Dermatologic Surgery.